Land: Ierland
Taal: Engels
Bron: HPRA (Health Products Regulatory Authority)
AZELAIC ACID
Intendis GmbH
20/2 %w/w
Cream
2007-07-27
IRISH MEDICINES BOARD ACTS 1995 AND 2006 MEDICINAL PRODUCTS(CONTROL OF PLACING ON THE MARKET)REGULATIONS,2007 (S.I. NO.540 OF 2007) PA1407/006/002 Case No: 2069031 The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to INTENDIS GMBH MAX-DOHRN-STR. 10, D-10589 BERLIN, GERMANY an authorisation, subject to the provisions of the said Regulations, in respect of the product SKINOREN 20% W/W CREAM The particulars of which are set out in Part I and Part II of the attached Schedule. The authorisation is also subject to the general conditions as may be specified in the said Regulations as listed on the reverse of this document. This authorisation, unless previously revoked, shall continue in force from 14/12/2009. Signed on behalf of the Irish Medicines Board this ________________ A person authorised in that behalf by the said Board. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 14/12/2009_ _CRN 2069031_ _page number: 1_ PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Skinoren 20% w/w Cream. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 g Skinoren cream contains 200 mg (20 % w/w) micronized azelaic acid. For excipients, see section 6.1. 3 PHARMACEUTICAL FORM Cream. White opaque cream. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS In the treatment of acne vulgaris. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION In general, Skinoren should be applied twice a day (mornings and evenings) as directed. Before Skinoren is applied, the skin should be thoroughly cleaned with plain water and dried. A mild skin-cleansing agent may be used. Skinoren should be applied to the affected areas of skin and rubbed well in. It Lees het volledige document